ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pralsetinib

Also written as “Pralsetinib” and “pralsetinib (BLU-667)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Medullary, led by 2 companies.

Drug pagePralsetinib: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 3, 20207 company-led studies, 3 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only62 open or runningphase 3since Jan 3, 2020Jan 20, 2017Nov 30, 2026phase 2 · NCT04302025
Rigel Pharmaceuticals11 open or runningphase 4since Jul 9, 2026Jul 9, 2026Jul 30, 2027phase 4 · NCT07704658

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Rigel Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2018Named pralsetinibINNProposed as its International Nonproprietary Name in WHO's List 120
  2. Jul 9, 2026First study: phase 4 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07704658 · 12 planned · Spain

Ahead

  1. Jul 30, 2027Primary completion: phase 4 study in Carcinoma, Non-Small-Cell LungNCT07704658

TargetBeta

“An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, ”NCIt, by rule
“Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
selpercatinibruleEli Lillyphase 419

Studies

The one study Rigel Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07704658Carcinoma, Non-Small-Cell Lung · Spain4RecruitingJul 30, 202712

How it is read

Names in the registry

  • “Pralsetinib”, 6 entries
  • “pralsetinib (BLU-667)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.